Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations
Maria Chiara Fontana(Istituto Oncologico Romagnolo), Giovanni Martinelli(University of Bologna), Rossella De Tommaso(University of Bologna), Simona Soverini(University of Bologna), Anna Ferrari(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Chiara Sartor(University of Bologna), Emanuela Ottaviani(University of Bologna), Giovanni Marconi(University of Bologna), Eugenia Franchini(University of Bologna), Sarah Parisi(University of Bologna), Jelena D. Milosevic Feenstra(Austrian Academy of Sciences), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Marco Manfrini(University of Padua), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Nicoletta Testoni(Thrombolysis in Myocardial Infarction Study Group), Viviana Guadagnuolo(University of Bologna), Elena Tenti(University of Bologna), Antonella Padella(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Samantha Bruno(University of Bologna), Róbert Královics(Medical University of Vienna)
Cited by 2
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644